These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36155528)

  • 1. Early Dysbiosis and Dampened Gut Microbe Oscillation Precede Motor Dysfunction and Neuropathology in Animal Models of Parkinson's Disease.
    Liang F; Chen CY; Li YP; Ke YC; Ho EP; Jeng CF; Lin CH; Chen SK
    J Parkinsons Dis; 2022; 12(8):2423-2440. PubMed ID: 36155528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The link between the gut microbiota and Parkinson's Disease: A systematic mechanism review with focus on α-synuclein transport.
    Nielsen SD; Pearson NM; Seidler K
    Brain Res; 2021 Oct; 1769():147609. PubMed ID: 34371014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
    Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
    Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
    Lai F; Jiang R; Xie W; Liu X; Tang Y; Xiao H; Gao J; Jia Y; Bai Q
    Neurochem Res; 2018 Oct; 43(10):1986-1999. PubMed ID: 30171422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
    Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
    mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Gut Microbiota Alterations on Motor, Gastrointestinal, and Behavioral Phenotype in a Mouse Model of Parkinson's Disease.
    Radisavljevic N; Cirstea M; Bauer K; Lo C; Metcalfe-Roach A; Bozorgmehr T; Bar-Yoseph H; Brett Finlay B
    J Parkinsons Dis; 2022; 12(5):1479-1495. PubMed ID: 35599496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fiber deprivation and microbiome-borne curli shift gut bacterial populations and accelerate disease in a mouse model of Parkinson's disease.
    Schmit KJ; Garcia P; Sciortino A; Aho VTE; Pardo Rodriguez B; Thomas MH; Gérardy JJ; Bastero Acha I; Halder R; Cialini C; Heurtaux T; Ostahi I; Busi SB; Grandmougin L; Lowndes T; Singh Y; Martens EC; Mittelbronn M; Buttini M; Wilmes P
    Cell Rep; 2023 Sep; 42(9):113071. PubMed ID: 37676767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease.
    Lin CH; Chen CC; Chiang HL; Liou JM; Chang CM; Lu TP; Chuang EY; Tai YC; Cheng C; Lin HY; Wu MS
    J Neuroinflammation; 2019 Jun; 16(1):129. PubMed ID: 31248424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.
    Vidal-Martinez G; Chin B; Camarillo C; Herrera GV; Yang B; Sarosiek I; Perez RG
    J Parkinsons Dis; 2020; 10(1):185-192. PubMed ID: 31561385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal microbiota from patients with Parkinson's disease intensifies inflammation and neurodegeneration in A53T mice.
    Yang H; Shao Y; Hu Y; Qian J; Wang P; Tian L; Ni Y; Li S; Al-Nusaif M; Liu C; Le W
    CNS Neurosci Ther; 2024 Aug; 30(8):e70003. PubMed ID: 39161161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota and metabolites of α-synuclein transgenic monkey models with early stage of Parkinson's disease.
    Yan Y; Ren S; Duan Y; Lu C; Niu Y; Wang Z; Inglis B; Ji W; Zheng Y; Si W
    NPJ Biofilms Microbiomes; 2021 Sep; 7(1):69. PubMed ID: 34475403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter hepaticus augmentation triggers Dopaminergic degeneration and motor disorders in mice with Parkinson's disease.
    Ahn EH; Liu X; Alam AM; Kang SS; Ye K
    Mol Psychiatry; 2023 Mar; 28(3):1337-1350. PubMed ID: 36543925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human gut microbiota and Parkinson's disease.
    Pant A; Bisht KS; Aggarwal S; Maiti TK
    Prog Mol Biol Transl Sci; 2022; 192(1):281-307. PubMed ID: 36280322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
    Dodiya HB; Forsyth CB; Voigt RM; Engen PA; Patel J; Shaikh M; Green SJ; Naqib A; Roy A; Kordower JH; Pahan K; Shannon KM; Keshavarzian A
    Neurobiol Dis; 2020 Feb; 135():104352. PubMed ID: 30579705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Yu J; Meng J; Qin Z; Yu Y; Liang Y; Wang Y; Min D
    J Neuroinflammation; 2023 May; 20(1):117. PubMed ID: 37208728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated multi-omics profiling highlights the benefits of resveratrol hydroxypropyl-β-cyclodextrin inclusion complex for A53T transgenic mice through the microbiota-gut-brain axis.
    Sun X; Feng S; Qin B; Ye J; Xie L; Gui J; Sang M
    Food Funct; 2024 Feb; 15(3):1489-1512. PubMed ID: 38227477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
    Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota dysbiosis contributes to α-synuclein-related pathology associated with C/EBPβ/AEP signaling activation in a mouse model of Parkinson's disease.
    Fang X; Liu S; Muhammad B; Zheng M; Ge X; Xu Y; Kan S; Zhang Y; Yu Y; Zheng K; Geng D; Liu CF
    Neural Regen Res; 2024 Sep; 19(9):2081-2088. PubMed ID: 38227539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.